Risk of second non-germ-cell cancer after treatment of a stage I-II testicular seminoma;Risque de deuxième cancer non germinal après traitement d'un séminome testiculaire de stade I-II

Progres en Urologie

Volumn 9, Issue 4, 1999, Pages 689-695

  Bachaud, Jean Marc ^a   Berthier, Frédéric ^b   Soulié, Michel ^c   Malavaud, Bernard ^d   Plante, Pierre ^c   Rischmann, Pascal ^d   Chevreau, Christine ^a   Grosclaude, Pascale ^b  

^a INSTITUT CLAUDIUS REGAUD   (France)

^b Registre des Cancers du Tarn   (France)

^c CHU RANGUEIL   (France)

^d CHU PURPAN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; ORCHIECTOMY; RADIATION DOSE; RISK FACTOR; SECOND CANCER; SEMINOMA; TESTIS TUMOR; TIME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; ORCHIECTOMY; RADIOTHERAPY DOSAGE; RISK FACTORS; SEMINOMA; TESTICULAR NEOPLASMS; TIME FACTORS;

EID: 0033194089     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. AKRE O., EKBOM A., HSEIH C.C., TRICOPOULOS D., ADAMI H.O.. Testicular nonseminomatous and seminoma in relation to perinatal characteristics. J. Natl. Cancer Inst., 1996, 88, 883-889.
2. BOKEMEYER C., SCHMOLL H.J. Secondary neoplasms following treatment of malignant germ cell tumors. J. Clin. Oncol,. 1993, 11, 1703-1709.
3. BOKEMEYER C., SCHMOLL H.J. Treatment of testicular cancer and the development of secondary malignancies. J. Clin. Oncol., 1995, 13, 283-292.
4. BOSL G.J., MOTZER R.J. Testicular germ-cell cancer. N. Engl. J. Med., 1997, 337, 242-253.
5. BRESLOW N.E., DAY N.E. Rates and rate standardization. In : Breslow N.E., Day N.E. Statistical methods in cancer research. Agency for Research on Cancer, 1987; IARC Sci. Pub. No 82, Vol. 2.
6. BRESLOW N.E., DAY N.E. Rates and rate standardization. In : Breslow N.E., Day N.E. Statistical methods in cancer research. Agency for Research on Cancer, 1987; IARC Sci. Pub. No 82, Vol. 2.
7. CHAO C.K., LAI P.P., MICHALSKI J.M., PEREZ C.A. Secondary malignancy among seminoma patients treated with adjuvant radiation therapy. Int. J. Radial. Oncol. Biol. Phys., 1995,4, 831-835.
8. COLEMAN M., DOUGLAS A., HERMON C., PETO J. Cohort study analysis with a fortran computer program. Int. J. Epidemiol., 1986, 15, 134-137.
9. EINHORN L.H. Radiotherapy in seminoma: more is not better. Int. J. Radiat. Oncol. Biol. Phys., 1982, 8, 309-310.
10. FOSSA S.D., LANGMARK F., AASS N., ANDERSEN A., LOTHE R., BORRESEN A.L. Second non germ-cell malignancies after radiotherapy of testicular cancer with or without chemotherapy. Br. J. Cancer. 1990, 61, 639-643.
11. HANKS G.E., HERRING D.E., KRAMER S. Pattern of care outcome studies: results of the national practice in seminoma of the testis. Int. J. Radial. Oncol. Biol. Phys., 1983, 9, 949-950.
12. HANKS G.E., PETERS T., OWEN J. Seminoma of the testis: Long term beneficial and deleterious results of radiation. Int. J. Radiat. Oncol. Biol. Phys., 1993, 24, 913-919.
13. HAY J.H., DUNCAN W., KERR G.R. Subsequent malignancies in patients irradiated for testicular tumors. Br. J. Radiol., 1984, 57, 597-602.
14. HEIMDAL K., OLSSON H., TRETLI S., BORRESEN A.L., FOSSA S.D. Risk of cancer in relatives of testicular cancer patients. Br. J. Cancer, 1996, 73, 970-973.
15. HELLBARDT A., MIRIMANOFF R.O., OBRADOVIC M., MERMILLOW B., PAUNIER J.P. The risk of second cancer in patients treated for testicular seminoma. Int. J. Radiat. Oncol. Biol. Phys., 1990, 18, 1327-1331.
16. HORWICH A., BELL J. Mortality and cancer incidence following radiotheray for seminoma of the testis. Radiother. Oncol., 1994, 30, 193-198.
17. JACOBSEN G.K., MELLEMGAARD A., ENGELHOLM S.A., MOLLER H. Increased incidence of sarcoma in patients treated for testicular seminoma. Eur. J. Cancer, 1993, 5, 664-668.
18. KALDOR J.M., DAY N.E., BAND P., CHOI N.W., CLARKE E.A., COLEMAN M.P., HAKAMA M., KOCH M., LANGMARK F., NEAL F.E., PETTERSSON F., POMPE-KIRN V., PRIOR P., STORM H.H. Second malignancies following testicular cancer, ovarian cancer and Hodgkin's disease: An international collaborative study among cancer registries. Int. J. Cancer. 1987, 39, 571-585.
19. LI M.C., WHITMORE W.F., GOLBEY R., GRABSTALD H. Effects of combined drug therapy on metastatic cancer of the testis. J.A.M.A., 1960, 174, 145-153.
20. MOLLER H., MELLEMGAARD A., JACOBSEN G.K., PEDERSEN D., STORM H.H. Incidence of second primary cancer following testicular cancer. Eur. J. Cancer, 1993, 5, 672-676.
21. OLIVER R.T.D., EDMONDS P.M., ONG J.Y.H., OSTROWSKI M.J., JAKSON A.W., BAILLE-JOHNSON H., WILLIAMS M.V., WILTSHIRE C.R., MOTT T., PRATT W.R., TRASK C.W.L., HOPE-STONE H.F. Pilot studies of 2 and 1 course carboplatin as adjuvant for Stage I seminoma: Should it be tested in a randomized trial against radiotherapy? Int. J. Radiat. Oncol. Biol. Phys., 1994, 29, 3-8.
22. OLIVER R.T.D., OLIVER J.C. Endocrine hypothesis for declining sperm count and rising testis cancer incidence. Lancet, 1996, 346, 339-340.
23. ROBINSON E., NEUGUT A.L., WYLIE P. Clinical aspects of postirradiation sarcomas. J. Natl. Cancer Inst., 1988, 80, 233-240.
24. TUCKER M.A., COLEMAN C.N., COX R.S., VARGHESE A., ROSENBERG S.A., Risk of second cancers after treatment for Hodgkin's disease. N. Engl. J. Med., 1988, 318, 76-81.
25. VAN DER MAASE H., SPECHT L., JACOBSEN G.K., et al. Surveillance following orchiectomy for stage I seminoma of the testis. Eur. J. Cancer. 1993, 29, 1931-1934.
26. VAN LEEUWEN F.E., STIGGELBOUT A.M., VAN DEN BELT-DUSEBOUT A.W., NOYON R., ELIEL M.R., VAN KERKHOFF E.H.M., DELEMARRE J.F.M., SOMERS R. Second cancer risk following testicular cancer: A follow-up study of 1,909 patients. J . Clin . Oncol., 1993, 11, 415-424.
27. WESTERGAARD T., OLSEN J.H., FRISCH M., KRONMAN M., NEILSEN J.W., MELBYE M. Cancer risk in fathers and brothers of testicular cancer patients in Denmark: a population-based study. Int. J. Cancer. 1996, 66, 627-631.